用于治疗银屑病的抗白细胞介素和白细胞介素疗法：当前证据及临床应用价值
Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness.
作者信息
Tsai Ya-Chu, Tsai Tsen-Fang
机构信息
Far Eastern Memorial Hospital, New Taipei City, Taiwan.
National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, 100, Taiwan.
出版信息
Ther Adv Musculoskelet Dis. 2017 Nov;9(11):277-294. doi: 10.1177/1759720X17735756. Epub 2017 Nov 6.
Abstract
Anti-interleukin (IL) therapies have emerged as a major treatment for patients with moderate-to-severe psoriasis. This article reviews the up-to-date results of pivotal clinical trials targeting the interleukins used for the treatment of psoriasis, including IL-1, IL-2, IL-6, IL-8, IL-10, IL-12, IL-17, IL-20, IL-22, IL-23, IL-36 and bispecific biologics IL-17A/tumor necrosis factor alpha (TNF-α). Cytokines involved in the circuits of psoriasis inflammation without ongoing clinical trials are also mentioned (IL-9, IL-13, IL-15, IL-16, IL-18, IL-19, IL-21, IL-24, IL-27, IL-33, IL-35, IL-37, and IL-38).
摘要
抗白细胞介素（IL）疗法已成为中重度银屑病患者的主要治疗方法。本文综述了针对用于治疗银屑病的白细胞介素的关键临床试验的最新结果，包括IL-1、IL-2、IL-6、IL-8、IL-10、IL-12、IL-17、IL-20、IL-22、IL-23、IL-36以及双特异性生物制剂IL-17A/肿瘤坏死因子α（TNF-α）。还提到了参与银屑病炎症通路但目前尚无临床试验的细胞因子（IL-9、IL-13、IL-15、IL-16、IL-18、IL-19、IL-21、IL-24、IL-27、IL-33、IL-35、IL-37和IL-38）。
相似文献
1
Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness.用于治疗银屑病的抗白细胞介素和白细胞介素疗法：当前证据及临床应用价值
Ther Adv Musculoskelet Dis. 2017 Nov;9(11):277-294. doi: 10.1177/1759720X17735756. Epub 2017 Nov 6.
2
Relevance of Inflammatory Cytokine mRNA Expression of Tumour Necrosis Factor- Alpha (TNF α), Interleukin 17A (IL 17A) and Interleukin 6 (IL 6) in Indian Patients with Psoriasis.肿瘤坏死因子-α（TNFα）、白细胞介素17A（IL 17A）和白细胞介素6（IL 6）炎性细胞因子mRNA表达在印度银屑病患者中的相关性
Indian Dermatol Online J. 2022 Mar 3;13(2):229-233. doi: 10.4103/idoj.idoj_306_21. eCollection 2022 Mar-Apr.
3
Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis.炎症的血细胞生物标志物和细胞因子水平作为预测银屑病患者对生物制剂反应的指标。
Int J Mol Sci. 2023 Mar 24;24(7):6111. doi: 10.3390/ijms24076111.
4
The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.TNF/IL-23/IL-17 轴——头对头试验比较不同生物制剂治疗银屑病的疗效。
Scand J Immunol. 2020 Oct;92(4):e12946. doi: 10.1111/sji.12946.
5
New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors.中重度斑块状银屑病的新型及新兴生物疗法：IL-17和IL-23抑制剂的作用机制原理及近期临床数据
Dermatol Ther. 2015 Jul-Aug;28(4):179-93. doi: 10.1111/dth.12251.
6
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.生物制剂治疗慢性斑块状银屑病与心血管事件的相关性：随机对照试验的荟萃分析。
JAMA. 2011 Aug 24;306(8):864-71. doi: 10.1001/jama.2011.1211.
7
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).临床实践中生物制剂的疗效比较：一项国际观察性银屑病患者健康结局研究（PSoHO）的第 12 周主要结局。
J Eur Acad Dermatol Venereol. 2022 Nov;36(11):2087-2100. doi: 10.1111/jdv.18376. Epub 2022 Jul 29.
8
Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics.托斯卡纳共识治疗中重度银屑病：更新和关注抗 IL-17 和抗 IL-23 生物制剂治疗中定位的实用指南。
Ital J Dermatol Venerol. 2022 Dec;157(6):469-479. doi: 10.23736/S2784-8671.22.07355-8. Epub 2022 Jul 5.
9
Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis.靶向 TNF-α/IL-23/IL-17 轴的生物制剂在银屑病和银屑病关节炎中的疗效差异。
Cytokine. 2018 Nov;111:182-188. doi: 10.1016/j.cyto.2018.08.025. Epub 2018 Aug 29.
10
Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a.抗体在银屑病治疗中的应用：IL-12/23 p40和IL-17a
Semin Cutan Med Surg. 2016 Jun;35(4 Suppl 4):S74-7.
引用本文的文献
1
Predictors of PASI90 response in patients with psoriasis treated with ınterleukin ınhibitors: observational cohort study.接受白细胞介素抑制剂治疗的银屑病患者达到PASI90缓解的预测因素：观察性队列研究。
An Bras Dermatol. 2025 Jun 18;100(4):501132. doi: 10.1016/j.abd.2025.501132.
2
Interleukin in Immune-Mediated Diseases: An Updated Review.免疫介导疾病中的白细胞介素：最新综述
Mol Biotechnol. 2024 Dec 23. doi: 10.1007/s12033-024-01347-8.
3
Th22 cells promote the transition from homeostatic to reactive microglia in diabetic encephalopathy.辅助性T细胞22亚群（Th22细胞）促进糖尿病性脑病中稳态小胶质细胞向反应性小胶质细胞的转变。
Acta Diabetol. 2025 May;62(5):633-650. doi: 10.1007/s00592-024-02384-0. Epub 2024 Dec 4.
4
Xiaoyin-anshen formula alleviates psoriasis complicated by sleep disturbances by regulating melatonin, antioxidant enzymes, and pro-inflammatory cytokines in mice.消银安神方通过调节小鼠体内褪黑素、抗氧化酶和促炎细胞因子来缓解伴有睡眠障碍的银屑病。
Front Pharmacol. 2024 Oct 1;15:1427985. doi: 10.3389/fphar.2024.1427985. eCollection 2024.
5
Exploring the Therapeutic Potential of Natural Compounds in Psoriasis and Their Inclusion in Nanotechnological Systems.探索天然化合物在银屑病中的治疗潜力及其在纳米技术系统中的应用
Antioxidants (Basel). 2024 Jul 28;13(8):912. doi: 10.3390/antiox13080912.
6
Evaluation of THP-1 and Jurkat Cell Lines Coculture for the In Vitro Assessment of the Effects of Immunosuppressive Substances.用于体外评估免疫抑制物质作用的THP-1和Jurkat细胞系共培养的评估
Toxics. 2024 Aug 19;12(8):607. doi: 10.3390/toxics12080607.
7
Epidermal Barrier Parameters in Psoriasis: Implications in Assessing Disease Severity.银屑病中的表皮屏障参数：对评估疾病严重程度的意义。
J Pers Med. 2024 Jul 5;14(7):728. doi: 10.3390/jpm14070728.
8
Macrophage Functions in Psoriasis: Lessons from Mouse Models.银屑病中巨噬细胞的功能：来自小鼠模型的启示。
Int J Mol Sci. 2024 May 13;25(10):5306. doi: 10.3390/ijms25105306.
9
Ursolic Acid Formulations Effectively Induce Apoptosis and Limit Inflammation in the Psoriasis Models In Vitro.熊果酸制剂在体外银屑病模型中有效诱导细胞凋亡并限制炎症。
Biomedicines. 2024 Mar 25;12(4):732. doi: 10.3390/biomedicines12040732.
10
Bioinformatic Analysis to Identify and Cellular Experiments to Validate Autophagy-related Genes in Psoriasis.生物信息学分析鉴定银屑病自噬相关基因及细胞实验验证
Comb Chem High Throughput Screen. 2024;27(9):1318-1328. doi: 10.2174/0113862073238968230920054712.
本文引用的文献
1
Inhibition of IL-17A by secukinumab shows no evidence of increased infections.司库奇尤单抗对白细胞介素-17A的抑制作用未显示出感染增加的迹象。
Clin Transl Immunology. 2017 Aug 25;6(8):e152. doi: 10.1038/cti.2017.34. eCollection 2017 Aug.
2
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.替西单抗与安慰剂或依那西普治疗慢性斑块型银屑病（reSURFACE 1 和 reSURFACE 2）：两项随机对照、3 期临床试验的结果。
Lancet. 2017 Jul 15;390(10091):276-288. doi: 10.1016/S0140-6736(17)31279-5. Epub 2017 Jun 6.
3
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.比较依奇珠单抗和乌司奴单抗治疗中重度银屑病：IXORA-S 三期研究 24 周结果。
Br J Dermatol. 2017 Oct;177(4):1014-1023. doi: 10.1111/bjd.15666. Epub 2017 Jul 19.
4
New Interleukins in Psoriasis and Psoriatic Arthritis Patients: The Possible Roles of Interleukin-33 to Interleukin-38 in Disease Activities and Bone Erosions.银屑病和银屑病关节炎患者中的新型白细胞介素：白细胞介素-33至白细胞介素-38在疾病活动和骨质侵蚀中的可能作用
Dermatology. 2017;233(1):37-46. doi: 10.1159/000471798. Epub 2017 May 10.
5
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.利纳西珠单抗与乌司奴单抗治疗中重度斑块状银屑病的疗效比较。
N Engl J Med. 2017 Apr 20;376(16):1551-1560. doi: 10.1056/NEJMoa1607017.
6
Limited Presence of IL-22 Binding Protein, a Natural IL-22 Inhibitor, Strengthens Psoriatic Skin Inflammation.天然白细胞介素-22抑制剂白细胞介素-22结合蛋白的低表达会加重银屑病皮肤炎症。
J Immunol. 2017 May 1;198(9):3671-3678. doi: 10.4049/jimmunol.1700021. Epub 2017 Mar 29.
7
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. Guselkumab，一种抗白细胞介素-23 单克隆抗体，与阿达木单抗治疗中重度斑块状银屑病的疗效和安全性比较：来自 III 期、双盲、安慰剂和阳性对照的 VOYAGE 2 试验的结果。
J Am Acad Dermatol. 2017 Mar;76(3):418-431. doi: 10.1016/j.jaad.2016.11.042. Epub 2017 Jan 2.
8
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. Guselkumab，一种抗白细胞介素-23 单克隆抗体，与阿达木单抗相比，用于中重度银屑病患者的连续治疗：来自 III 期、双盲、安慰剂和活性对照 VOYAGE 1 试验的结果。
J Am Acad Dermatol. 2017 Mar;76(3):405-417. doi: 10.1016/j.jaad.2016.11.041. Epub 2017 Jan 2.
9
Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.皮肌炎中的特异性自身抗体：区分不同临床亚组的有用工具。
Arch Dermatol Res. 2017 Mar;309(2):87-95. doi: 10.1007/s00403-016-1704-1. Epub 2016 Dec 7.
10
Are interleukin-15 and -22 a new pathogenic factor in pustular palmoplantar psoriasis?白细胞介素-15和-22是脓疱型掌跖银屑病的新致病因素吗？
Postepy Dermatol Alergol. 2016 Oct;33(5):336-339. doi: 10.5114/ada.2016.62838. Epub 2016 Oct 21.
Zotero 插件